CORAL GABLES, FL / ACCESSWIRE / March 27, 2018 / The biotechnology industry continues to recover this week. After having stumbled last week, along with the overall market, benchmarks based on the NASDAQ Biotechnology Index (IBB) continued to climb higher on Tuesday. Early premarket trading saw the index reach $108.69 and marked a 3.3% move up from Monday's low. In addition to this, U.S. stock futures indicated a rise at the open Tuesday, which set the Dow industrials on pace to add to Monday's 660+ point gain.
While the markets pull north, biotech companies have released positive news this week that seems to have attracted more attention. These include GT Biopharma (OTCQB: GTBP) and Ekso Bionics (NASDAQ: EKSO).
GT Biopharma (GTBP)'s pipeline includes therapies for numerous diseases. Earlier this week the company announced that it has completed the analysis of pharmacokinetic data from its Phase 1 clinical trial for GTP-004, its promising treatment for the symptoms of myasthenia gravis. Over recent weeks the company has been focused on building their leadership team, which includes a long list of finance and biotechnology industry veterans.
Most recently the company appointed Shawn Cross as CEO and Chairman. Mr. Cross was a Managing Director, and senior calling officer focused on the biopharmaceutical industry, in Healthcare Investment Banking at Deutsche Bank Securities Inc. (DB). He was also a Managing Director in the Wells Fargo Securities, LLC. (WF) Healthcare Group.
For More on GT Biopharma, Click Here For Your Full Report
Also making headlines this morning is Ekso Bionics (EKSO). Though the company does not have a breakthrough drug therapy, it is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications.
In a tweet that was posted on Monday, the company said, "We have exciting news on its way! Stay tuned to find out the latest at Ekso Bionics."
Following this tweet, shares of the company climbed to highs of $2.20 before closing at $2.07. Pre-market activity on Tuesday shows shares trading around $2.12
BIOTECHSTOCKS
About BiotechStocks.com
Biotech Stocks (www.biotechstocks.com) is your best resource for today's emerging biotech industry. Whether you're looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to. Learn as much as you can, then decide whether a position in publicly traded Biotech related stocks is right for you.
BIOTECHSTOCKS.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April 30, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer Here.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com.
NO WARRANTY
BTS, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Contact:
SOURCE: BiotechStocks.com
